Category Archives: News from Other Sources

Trial participants receiving the highest dose showed symptom improvement in the first stage of an ongoing phase 2 trial of this experimental drug in ALS.

Trial participants receiving the highest dose showed symptom improvement in the first stage of an ongoing phase 2 trial of this experimental drug in ALS.

IDMC-8, held Nov. 30-Dec. 3, 2011, explored disease mechanisms, clinical aspects and ideas for future therapies in myotonic muscular dystrophy.

A phase 1 trial of Ultragenyx’ treatment for hereditary inclusion-body myositis caused by GNE mutations is taking place in New York and California.

Four $2,500 college scholarships for children of parents with ALS are available; application deadline is Jan. 6, 2012.

A collaboration between PTC Therapeutics and Swiss biotech Roche may speed development of experimental treatments for spinal muscular atrophy.

A phase 1 trial of Ultragenyx’ treatment for hereditary inclusion-body myositis caused by GNE mutations is taking place in New York and California.

MDA is hosting ‘viewing parties’ around the country to watch a live session from the International Myotonic Dystrophy Consortium.

Clinical trial data for the experimental drug show slowing of symptom progression and increase in survival time in people with ALS.

AVI BioPharma is developing two new exon-skipping drugs; GlaxoSmithKline will conduct more trials of GSK2402968, for which participants are being recruited.